Advanced search
Publication Cover
Postgraduate Medicine Volume 123, 2011 - Issue 5
Submit an article Journal homepage
110
Views
9
CrossRef citations to date
0
Altmetric
Clinical Focus: ADHD, Depression, Pain, and Neurological Disorders

Exploring the Impact of Once-Daily OROS® Methylphenidate (MPH) on Symptoms and Quality of Life in Children and Adolescents with ADHD Transitioning from Immediate-Release MPH

Andreas Kordon Klinik für Psychiatrie und Psychotherapie, Lübeck, Germany
, MD, PhD,
Kirsten Stollhoff Praxis für Kinderneurologie, Hamburg, Germany
, MD,
Käte Niederkirchner Praxis für Kinder und Jugendmedizin, Friedrichsfelde, Germany
, MD,
Fritz Mattejat Klinik für Kinder- und Jugendpsychiatrie und -psychotherapie am Universitätsklinikum Gießen und Marburg, Marburg, Germany
, PhD,
Klaus Rettig G.E.M. Gesellschaft für Evaluation und Qualitätssicherung in der Medizin mbH, Meerbusch, Germany
, MSc (Psych), MSc (Math) &
Barbara Schäuble Janssen EMEA Medical Affairs, Neuss, GermanyCorrespondence[email protected]
, MD, PhD
Pages 27-38 | Published online: 13 Mar 2015

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Merve Cikili Uytun, Fatih Hilmi Çetin & Zehra Babadağı. (2019) Parent-reported social problems and clinician-evaluated adverse effects may be differentially affected by differing extended release methylphenidate formulations: a prospective, naturalistic study from Turkey. Psychiatry and Clinical Psychopharmacology 29:4, pages 722-729.
Read now
Wen-Jiun Chou, Liang-Jen Wang, Chien-Ho Lin, Sun-Yuan Liang, Vincent Chin-Hung Chen, Yuh-Ming Hou, Rong-Rong Huang, Miao-Chun Chou, Chi-Yung Shang, Chi-Pui Ho & Meng-Chuan Lai. (2018) Social adjustment and family function after drug switch from IR-methylphenidate to OROS-methylphenidate in patients with attention-deficit/hyperactivity disorder. Neuropsychiatric Disease and Treatment 14, pages 2783-2791.
Read now
Ann C. Childress. (2016) Methylphenidate HCL for the treatment of ADHD in children and adolescents. Expert Opinion on Pharmacotherapy 17:8, pages 1171-1178.
Read now

Articles from other publishers (6)

Miyuki Takahashi, Arika Sugiyama, Ran Wei, Shizuka Kobayashi, Kimiko Fukuda, Hironori Nishino, Roka Takahashi, Koji Tsutsumi, Ichiro Kita, Kanae Ando, Toshiya Manabe, Hiroyuki Kamiguchi, Mineko Tomomura & Shin-ichi Hisanaga. (2020) Hyperactive and impulsive behaviors of LMTK1 knockout mice. Scientific Reports 10:1.
Crossref
D. M. Foreman & S. Timimi. (2018) Attention-deficit hyperactivity disorder (ADHD): progress and controversy in diagnosis and treatment. Irish Journal of Psychological Medicine 35:3, pages 251-257.
Crossref
Ole Jakob Storebø, Nadia Pedersen, Erica Ramstad, Maja Laerke Kielsholm, Signe Sofie Nielsen, Helle B Krogh, Carlos R Moreira-Maia, Frederik L Magnusson, Mathilde Holmskov, Trine Gerner, Maria Skoog, Susanne Rosendal, Camilla Groth, Donna Gillies, Kirsten Buch Rasmussen, Dorothy Gauci, Morris Zwi, Richard Kirubakaran, Sasja J Håkonsen, Lise Aagaard, Erik Simonsen & Christian Gluud. (2018) Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. Cochrane Database of Systematic Reviews.
Crossref
Susan R. Berkowicz, Travis J. Featherby, Zhengdong Qu, Aminah Giousoh, Natalie A. Borg, Julian I. Heng, James C. Whisstock & Phillip I. Bird. (2016) Brinp1 −/− mice exhibit autism-like behaviour, altered memory, hyperactivity and increased parvalbumin-positive cortical interneuron density. Molecular Autism 7:1.
Crossref
Yi Su, Haibo Li, Yixin Chen, Fang Fang, Tong Xu, Haiping Lu, Ling Xie, Jianmin Zhuo, Jiazhi Qu, Li Yang & Yufeng Wang. (2015) Remission Rate and Functional Outcomes During a 6-Month Treatment With Osmotic-Release Oral-System Methylphenidate in Children With Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology 35:5, pages 525-534.
Crossref
Martin A. Katzman & Tia Sternat. (2014) A Review of OROS Methylphenidate (Concerta®) in the Treatment of Attention-Deficit/Hyperactivity Disorder. CNS Drugs 28:11, pages 1005-1033.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.